Clinician Resource Library: Informational Handouts Click below on each of the topical handouts to view and print copies on demand. You may also order a free Welcome Kit which includes a
MRD-guided treatment with ibrutinib plus venetoclax significantly improved quality of life for patients with relapsed / refractory CLL.
NX-5948 is a novel type of drug, classified as a BTK degrader, and it has shown promising early clinical data.
CLL Society awarded Dr. Nancy Musoke a research grant for his project on Curcumin, Exercise and Placebo Effects on CLL / SLL Progression and Immune Function.
Though it is still early on, rocbrutinib appears to be effective in CLL patients with prior BTKi resistance mutations, and it is generally well-tolerated.
The BTK degrader BGB-16673 shows promise in relapsed CLL. By degrading or destroying BTK instead of blocking it, degraders may overcome resistance.
Pirtobrutinib provides longer progression-free survival and is safer than idelalisib-rituximab and bendamustine-rituximab for treating relapsed CLL.
Join CLL Society and Dr. Deborah Stephens to learn how a comprehensive approach to well-being can complement your CLL care.
MEDICINE CABINET: MEDICATION SIDE EFFECTS Download and Print This Medication Sheet Many common side effects can occur with any of the chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) drugs.
